Concepedia

Author

Lilly East

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

L. East, Lilly East, Lindsey F. East

19

Publications

282

Citations

7

H-Index

12

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Ghent UniversitySarepta Therapeutics (United States)Università Cattolica del Sacro CuoreSorbonne Université
LE

About

Lilly East is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacotherapy, medicine, and neuropharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

79

2

Pharmacology

1

1

23

3

Clinical Pharmacology

1

1

23

4

Clinical Trials

1

1

35

5

Pharmacokinetic Modeling

1

1

23

Lilly East

×

6

Publications

255

Citations

6

H-Index

YearCitations

Safety, tolerability, and pharmacokinetics of casimersen in patients with <scp>D</scp>uchenne muscular dystrophy amenable to exon <scp>45</scp> skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trial

Kathryn R. Wagner, Nancy L. Kuntz, E. Koenig,

Muscle & Nerve

2021

137

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Pedro Cahn, Richard Kaplan, Paul E. Sax,

The Lancet HIV

2017

35

Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir

Rajesh Krishna, Lilly East, Patrick Larson,

Journal of Pharmacy and Pharmacology

2016

25

Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen

Drew MacCannell, Zdenek Berger, Lilly East,

Neuromuscular Disorders

2021

23

Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping

Eugenio Mercuri, A. Seferian, Laurent Servais,

Neuromuscular Disorders

2023

21

Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose

Rajesh Krishna, Lilly East, Patrick Larson,

Biopharmaceutics & Drug Disposition

2016

14

Page 1